United Therapeutics completes enrollment for phase 3 PAH drug study

United Therapeutics (UTHR) has completed enrollment for its Phase 3 ADVANCE OUTCOMES study of ralinepag, a potential once-daily oral treatment for pulmonary arterial hypertension, with top-line data anticipated in H1 2026. This development, supported by UTHR's strong financial health and positive analyst outlooks, occurs amidst an increasingly competitive PAH market, as Insmed recently reported positive Phase 2b results for its own PAH candidate and Liquidia Technologies secured a legal win enabling the potential launch of Yutrepia, a competitor to UTHR's existing Tyvaso.

Analysis

United Therapeutics (UTHR) has achieved a key clinical milestone by completing enrollment for its phase 3 ADVANCE OUTCOMES study for ralinepag, a potential once-daily oral treatment for pulmonary arterial hypertension (PAH), with top-line data not expected until the first half of 2026. This long-term development is supported by the company's exceptional financial health, evidenced by a perfect Piotroski Score of 9, an 89% gross profit margin, and 19.85% revenue growth over the last twelve months. While ralinepag showed promise in earlier studies, including a 29.8% reduction in pulmonary vascular resistance in a phase 2 trial, the competitive landscape is intensifying. Insmed recently announced positive Phase 2b data for its own PAH candidate, and more immediately, Liquidia Technologies has received a favorable legal ruling that clears the path for the launch of Yutrepia, a direct competitor to UTHR's established drug, Tyvaso. Despite these mounting competitive pressures, analyst sentiment on UTHR remains positive, with Leerink Partners and TD Cowen reiterating Outperform and Buy ratings, respectively, citing confidence in the company's pipeline and existing treatments.

Key Decisions for Investors

• Investors should monitor the commercial launch and market penetration of Liquidia's Yutrepia in the coming quarters to assess the real-world impact on United Therapeutics' Tyvaso sales, which is a key near-term risk.
• The ralinepag phase 3 data readout in H1 2026 represents a significant long-term catalyst, but the extended timeline requires patience and exposes the investment to interim market and competitive shifts.
• Consider the company's robust financial position, with high margins and a perfect Piotroski score, as a potential buffer against near-term stock volatility arising from competitive news.
• Closely track clinical developments from competitors like Insmed, as the evolving PAH treatment landscape will be critical in determining ralinepag's ultimate market potential and UTHR's long-term dominance in the space.